Evidence map›Paper›PMID 33952261›Full record

Observational studyRespiratory research2021

Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis.

Theodoros Karampitsakos, Sebastiano Torrisi, Katerina Antoniou, Effrosyni Manali, Ioanna Korbila, Ourania Papaioannou, Fotios Sampsonas, Matthaios Katsaras, Eirini Vasarmidi, Despoina Papakosta and 21 more

Open access · goldAbstract readMulticenter StudyObservational StudyValidation Study
In one paragraph

Observational study in Respiratory research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.

  1. Peripheral blood monocyte count and outcomes in patients with interstitial lung disease: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023
    Pooled it
  2. Article
  3. The transcriptome of CD14The European respiratory journal · 2026
    Article
  4. Article
  5. Protective Role of Octreotide in Acute and Chronic Lung Injuries.International journal of preventive medicine · 2026
    Article
  6. Article
  7. Precision Medicine Advances in Chronic Lung Diseases.International journal of molecular sciences · 2025
    Article
  8. Article
  9. Article
  10. Particles exposures and sarcoidosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

31 authors at 10 institutions in 2 countries.

Theodoros KarampitsakosDepartment of Respiratory Medicine, University Hospital of Patras, Patras, Greece.ORCID http://orcid.org/0000-0003-0804-6292
Sebastiano TorrisiCenter for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Katerina AntoniouLaboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
Effrosyni Manali2nd Pulmonary Medicine Department, "ATTIKON" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ioanna Korbila2nd Pulmonary Medicine Department, "ATTIKON" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ourania PapaioannouDepartment of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
Fotios SampsonasDepartment of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
Matthaios KatsarasDepartment of Respiratory Medicine, University Hospital of Patras, Patras, Greece.
Eirini VasarmidiLaboratory of Molecular and Cellular Pneumonology, Department of Respiratory Medicine, Faculty of Medicine, University of Crete, Heraklion, Crete, Greece.
Despoina PapakostaPulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
Kalliopi DomvriPulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
Eva FoukaPulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
Ioannis OrgantzisPulmonary Department, Medical School, Aristotle University of Thessaloniki, "G. PAPANIKOLAOU'' General Hospital, Exochi, Thessaloniki, Greece.
Zoe DaniilDepartment of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
Ilias DimeasDepartment of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
Paraskevi KirgouDepartment of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
Konstantinos I GourgoulianisDepartment of Respiratory Medicine, Medical School, University of Thessaly, Larissa, Greece.
Ilias C PapanikolaouRespiratory Medicine Department, "Corfu General Hospital", Corfu, Greece.
Katerina MarkopoulouPulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
Georgia KountiPulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
Eirini TsapakidouPulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
Efthymia PapadopoulouPulmonary Department "G. PAPANIKOLAOU" General Hospital, Thessaloniki, Greece.
Konstantinos TatsisDepartment of Respiratory Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Athena GogaliDepartment of Respiratory Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Konstantinos KostikasDepartment of Respiratory Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Vasilios TzilasFirst Academic Department of Pneumonology, Hospital for Thoracic Diseases, "SOTIRIA", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Serafeim Chrysikos5th Department of Pneumonology, Hospital for Thoracic Diseases, "SOTIRIA", Athens, Greece.
Spyridon Papiris2nd Pulmonary Medicine Department, "ATTIKON" University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Demosthenes Bouros *First Academic Department of Pneumonology, Hospital for Thoracic Diseases, "SOTIRIA", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Michael Kreuter *Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany.
Argyrios Tzouvelekis *Department of Respiratory Medicine, University Hospital of Patras, Patras, Greece. atzouvelekis@upatras.gr.
National and Kapodistrian University of Athens · GRAristotle University of Thessaloniki · GRGeneral University Hospital of Patras · GRG. Papanikolaou General Hospital · GRUniversity of Thessaly · GRUniversity of Ioannina · GRHeidelberg University · DEUniversity of Crete · GRCorfu General Clinic · GRSotiria General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIdiopathic Pulmonary Fibrosis (IPF) represents a chronic lung disease with unpredictable course.

methodsWe aimed to investigate prognostic performance of complete blood count parameters in IPF. Treatment-naïve patients with IPF were retrospectively enrolled from two independent cohorts (derivation and validation) and split into subgroups (high and low) based on median baseline monocyte count and red cell distribution width (RDW).

resultsOverall, 489 patients (derivation cohort: 300, validation cohort: 189) were analyzed. In the derivation cohort, patients with monocyte count ≥ 0.60 K/μL had significantly lower median FVC%pred [75.0, (95% CI 71.3-76.7) vs. 80.9, (95% CI 77.5-83.1), (P = 0.01)] and DLCO%pred [47.5, (95% CI 44.3-52.3) vs. 53.0, (95% CI 48.0-56.7), (P = 0.02)] than patients with monocyte count < 0.60 K/μL. Patients with RDW ≥ 14.1% had significantly lower median FVC%pred [75.5, (95% CI 71.2-79.2) vs. 78.3, (95% CI 76.0-81.0), (P = 0.04)] and DLCO%pred [45.4, (95% CI 43.3-50.5) vs. 53.0, (95% CI 50.8-56.8), (P = 0.008)] than patients with RDW < 14.1%. Cut-off thresholds from the derivation cohort were applied to the validation cohort with similar discriminatory value, as indicated by significant differences in median DLCO%pred between patients with high vs. low monocyte count [37.8, (95% CI 35.5-41.1) vs. 45.5, (95% CI 41.9-49.4), (P < 0.001)] and RDW [37.9, (95% CI 33.4-40.7) vs. 44.4, (95% CI 41.5-48.9), (P < 0.001)]. Patients with high monocyte count and RDW of the validation cohort exhibited a trend towards lower median FVC%pred (P = 0.09) and significantly lower median FVC%pred (P = 0.001), respectively. Kaplan-Meier analysis in the derivation cohort demonstrated higher all-cause mortality in patients with high (≥ 0.60 K/μL) vs. low monocyte count (< 0.60 K/μL) [HR 2.05, (95% CI 1.19-3.53), (P = 0.01)].

conclusionsIncreased monocyte count and RDW may represent negative prognostic biomarkers in patients with IPF.

Indexed as

Erythrocyte IndicesErythrocytesMonocytesAgedFemaleGreeceHumansIdiopathic Pulmonary FibrosisLeukocyte CountLungMalePredictive Value of TestsPrognosisReproducibility of ResultsRetrospective StudiesVital CapacityBiomarkersIdiopathic pulmonary fibrosisMonocyte countMortalityRDW

Identifiers

PMID33952261
PMCPMC8097815
OpenAlexW3158736422

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.